Suppression by cyproheptadine of human growth hormone and cortisol secretion during sleep.

Chihara, Kazuo; Kato, Yosuke; Maeda, Kiyoshi; Matsukura, Shigeru; Imura, Hiroo

doi:10.1172/jci108408

Cited by 82 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have reported increased GH levels during sleep after methysergide, a serotonin blocker of high pharmacologic specificity (7). In contrast, Chihara et al (15) have reported suppression of GH levels during sleep after cyproheptadine, a drug which has serotonin-, histamine-, acetylcholine-, and dopamine-blocking properties (37,38). Cyproheptadine is in fact a rather potent anticholinergic, and its ability to suppress GH levels during sleep may be related to its anticholinergic properties.…”

Section: Resultsmentioning

confidence: 99%

“…However, a variety of' fractors has been found to be capable of suppressing sleeprelated GH release, some without observable effect on slow-wave sleep (1,(13)(14)(15)(16)(17)(18)(19)(20)(21). These include: imipramine (1), medroxyprogesterone acetate (13), clomiphene (14), cyproheptadine (15), somatostatin (16), f'ree fatty acids (17), relative obesity (18,19), advanced age with acromegaly (20), the dwarfism associated with emotional deprivation (21), and chronic alcoholism (22). In most of' these instances, no effect on slow-wave sleep was noted, and in one study, the amount of' slow-wave sleep increased on nights when sleep-related GH secretion decreased (15).…”

Section: Introductionmentioning

confidence: 99%

“…These include: imipramine (1), medroxyprogesterone acetate (13), clomiphene (14), cyproheptadine (15), somatostatin (16), f'ree fatty acids (17), relative obesity (18,19), advanced age with acromegaly (20), the dwarfism associated with emotional deprivation (21), and chronic alcoholism (22). In most of' these instances, no effect on slow-wave sleep was noted, and in one study, the amount of' slow-wave sleep increased on nights when sleep-related GH secretion decreased (15). Further, inhibition of' slow-wave' sleep with flurazepam was not accompanied by any change in sleep-related GH secretion (23).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Methscopolamine Inhibition of Sleep-Related Growth Hormone Secretion

Mendelson¹,

Sitaram²,

Wyatt³

et al. 1978

J. Clin. Invest.

109

View full text Add to dashboard Cite

A B S T R A C T We have examined the effects of' cholinergic blockade with 0.5 mg methscopolamine bromide, intramuscularly, on sleep-related and insulininduced growth hormone (GH) secretion. 17 normal young men were studied; 8 had sleep studies, and 12 (including 3 who also had sleep studies) had insulin tolerance tests (ITT) with 0.1 U/kg of regular insulin. After an adjustment night in the sleep laboratory, saline control night and methscopolamine night studies were done in random se(luence; study procedures in-(cluded electroencephalographic, electromyographic, and electrooculographic recordings, and blood sampling every 20 min for hormone radioimmunoassays. Prolactin levels were also measured during sleep. For methscopolamine night studies, the mean overall control GH level of 2.89+0.44 ng/ml and the mean peak control GH level of' 11.09±3.11 ng/ml were dramatically reduced to 0.75±0.01 and 1.04+0.25 ng/ ml, respectively (P < 0.0001 and <0.001). Despite virtual absence of' GH secretion during the night in every study subject, no meas.ured sleep characteristic was affected by methscopolamine, including total slow-wave sleep ( methscopolamine had only a marginial effect oIn the GH response to insulin hypoglycemiiia. None of nine time points diff'ered significantly, as was also the case with peak levels, mean inerements, and areas under the curves (P > 0.2). Analysis of' variance did, however, indicate that the lower GH concentrations achieved during ITT after methscopolamine (average 31.7% below control) were significantly different than control concentrations. We conclude that the burst of' GH secretion which normally occurs after sleep onset is primed by a cholinergic mechanism which does not influence slow-wave sleep. Cholinergic mechanisms do not appear to play an important role in sleeprelated prolactin secretion. The contrast between the complete suppression of sleep-related GH release and the relatively small inhibitory effect on ITTinduced GH secretion suggests that the neurotransmitter mechanisms, and presumably the pathways, which subserve sleep-related GH secretion in man may be different from those which mediate the GH response to pharmacologic stimuli such as insulin.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Methscopolamine Inhibition of Sleep-Related Growth Hormone Secretion

Mendelson¹,

Sitaram²,

Wyatt³

et al. 1978

J. Clin. Invest.

109

View full text Add to dashboard Cite

show abstract

“…Diazepam has been shown to reduce ACTH output in man (Rees, 1970) and to reduce basal cortisol secretion in animals at low doses although in high doses cortisol secretion in animals is increased (Barlow, Knight & Sullivan, 1979 This finding has been replicated in patients with many diagnoses (General Practitioner Clinical Trials, 1970) and although the drug has been used in the treatment of anorexia nervosa systematic studies of its value in that condition have been few (Halmi & Goldberg, 1978). Endocrinological effects of cyproheptadine in man have been little studied but it has been found to reduce the growth hormone response to hypoglycaemia in normal volunteers (Bivens, Lebovitz & Feldman, 1973) and to suppress sleep related GH and cortisol release (Chihara, Kato, Maeda, Matsukara & Imura, 1976 (1979). Studies confined to particular disorders concern acromegaly (Thorner, Chait, Aitken, Bender, Bloom, Mortimer, Sanders, Stuart-Mason & Besser, 1975), Huntington's chorea (Caraceni et al, 1977) and Parkinsonism (Parkes, Debono & Marsden, 1976).…”

Section: Anxiolyticsmentioning

confidence: 99%

Neuroendocrine markers of CNS drug effects.

Johnstone¹,

Ferrier²

1980

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…It was previously reported that GH secretion during the night was hardly suppressed by bromocriptine in acromegaly [9].In the present case,concomitant administration of octreotide and bromocriptine considerably but insufficiently suppressed GH release during the night.Such patients with acromegaly could be effectively treated with an anti-serotoninergic agent which could inhibit hypothalamic GHRH involved in the hypersecretion of GH [23,24].…”

mentioning

confidence: 99%